Niaspan/Statin Combinations Improve Lipid Control, Study Says
This article was originally published in The Tan Sheet
Executive Summary
Data from a Phase IV efficacy trial of Kos' Niaspan, presented at the International Symposium on Atherosclerosis June 20 in Rome, supports the value of adding niacin to statin therapy for the treatment of high cholesterol, the company reported
You may also be interested in...
Kos Statin/Niacin Fixed Dose Combo To Be Supported By NHLBI-Funded Trial
The National Heart, Lung & Blood Institute will provide more than $20 mil. in funding for a clinical study comparing a simvastatin/niacin combination therapy to simvastatin alone for prevention of cardiovascular events
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands